Leukotac (inolimomab) / Mediolanum Pharma 
Welcome,         Profile    Billing    Logout  
 0 Diseases   3 Trials   3 Trials   40 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Leukotac (inolimomab) / Mediolanum Pharma
EiFFEL, NCT04289103: Evaluation of EFficacy and SaFEty of Leukotac (Inolimomab) in Pediatric Patients With SR-aGvHD

Not yet recruiting
3
65
NA
Inolimomab (Leukotac)
ElsaLys Biotech
Steroid Refractory GVHD
12/22
06/24
2006-005019-81: A European Open-Label, Multicentre, Phase II Study of Inolimomab in the Treatment of Primary Steroid Resistant Acute Graft versus Host Disease (aGvHD) following allogeneic Stem Cell Transplantation for Hematological Malignancies in Adult patients

Ongoing
2
20
Europe
LEUKOTAC® (Inolimomab), B-B10,
OPi
For treatment of patients with Primary Steroid Resistant Acute Graft versus Host Disease (aGvHD) following allogeneic Stem Cell Transplantation for Hematological Malignancies in Adult patients
 
 
NCT05047328: Early Access Program With Inolimomab in Steroid-refractory Acute Graft Versus Host Disease

Available
N/A
Europe
inolimomab, Leukotac
ElsaLys Biotech
Steroid Resistant Acute Graft Versus Host Disease
 
 

Download Options